Table 3. Relapse or Mortality Among Patients Who Survived More Than 15 Months After Cancer Diagnosisa.
| Colorectal | NSCLC | Prostate | Breast | |
|---|---|---|---|---|
| Relapse or deathb | ||||
| HIV-infected patients | 29 | 26 | 138 | 44 |
| Long-term outcomes (% patients) | 16 (55.2) | 19 (73.1) | 60 (43.5) | 24 (54.6) |
| HIV-uninfected patients | 43 167 | 21 932 | 104 465 | 88 591 |
| Long-term outcomes (% patients) | 25 512 (59.1) | 15 487 (70.6) | 43 205 (41.4) | 41 639 (47.0) |
| Adjusted HR (95% CI) | 1.58 (0.97-2.58) | 1.23 (0.79-1.93) | 1.32 (1.03-1.71) | 1.63 (1.09-2.43) |
| P value | .07 | .36 | .03 | .02 |
| Relapse or cancer-specific death | ||||
| Cancer outcomes in HIV-infected, No. (%) | NRc | 12 (46.2) | 35 (25.4) | 13 (29.6) |
| Cancer outcomes in HIV-uninfected, No. (%) | 11 431 (26.5) | 10 655 (48.6) | 24 242 (23.2) | 17 512 (19.8) |
| Adjusted HR (95% CI) | 1.51 (0.78-2.90) | 1.17 (0.67-2.07) | 1.28 (0.92-1.78) | 1.90 (1.10-3.28) |
| P value | .22 | .58 | .15 | .02 |
Abbreviations: HR, hazard ratio; NR, not reported; NSCLC, non–small cell lung cancer.
Models were adjusted for age, sex, race/ethnicity (white, nonwhite), median census tract income (<$30 000, $30 000-59 000, >$59 000, missing), year (1996-2004, 2005-2012), and stage at diagnosis, but sex adjustment was not applied to prostate and breast cancer.
Overall relapse/mortality outcome was defined as death (from any cause) or receipt of additional cancer treatment that occurred at least 15 months after cancer diagnosis; the relapse/cancer-specific mortality outcome was defined as death due specifically to cancer or receipt of additional treatment in this time frame. Follow-up time was calculated from cancer diagnosis until the earlier of either event.
Numbers lower than 11 are not reported in accordance with the Surveillance, Epidemiology, and End Results–Medicare data use agreement.